Clinical Trial

To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This observation study is designed as a prospective, multi-organ observation study to confirm the blood sugar control effect and safety of ENVLO tablet or Envlomet SR Tablet administration for 24 weeks in patients with type 2 diabetes who are scheduled to administer ENVLO tablet in the actual treatment environment.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-06-22; most recent amendment 2025-08-28.
Status change: Recruiting → Active, Not Recruiting 2025-01-21
Status change: Not Yet Recruiting → Recruiting 2024-05-14
Trial Details
NCT Number NCT05926414
Lead Sponsor Daewoong Pharmaceutical Co. LTD.
Conditions Diabetes Mellitus, Type 2
Enrollment 15,000 participants
Start Date 2023-09-21
Primary Completion 2025-01-17 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-02